A study announced the increased reliability of anterior-segment optical coherence tomography (AS-OCT) when used on patients after long-term dark adaptation.
A paper published in the Journal of Glaucoma has announced the increased reliability of anterior-segment optical coherence tomography (AS-OCT) when used on patients after long-term dark adaptation.
Dr Dejiao Li et al., Optoelectronics Research Centre, University of Southampton, Hampshire, UK, split 110 participants into 2 groups a study group and a control group. In the study group there were 70 suspects of primary angle closure and in the control group there were 40 normal participants. AS-OCT was used to measure the anterior chamber angle configuration and pupil diameter at both 3 minutes and 1.5 hours of dark adaptation.
The study group presented a significantly higher mean number of closed angle segments at 3 minutes of dark adaptation compared to 1.5 hours of dark adaptation or light conditions.
Pupil diameter was linked to the number of closed angle segments at 3 minutes of dark adaptation. Final intraocular pressure demonstrated an improved correlation with angle configuration segments at 3 minutes compared to 1.5 hours.
Overall, the dark room test with AS-OCT at 3 minutes was positive in a significantly high number of patients compared to dark room adaptation at 1.5 hours. The treatment was heavily advised as a method to identify glaucoma suspects.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.